Pages that link to "Q48852013"
Jump to navigation
Jump to search
The following pages link to Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab (Q48852013):
Displaying 50 items.
- Tau-aggregation inhibitor therapy for Alzheimer's disease (Q22252512) (← links)
- Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges (Q26745928) (← links)
- Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation (Q26748105) (← links)
- Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties (Q26765999) (← links)
- Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy (Q26781451) (← links)
- Anti-dementia medications: current prescriptions in clinical practice and new agents in progress (Q26795400) (← links)
- Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics (Q26822002) (← links)
- Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease (Q26829899) (← links)
- Testing the right target and right drug at the right stage (Q26864854) (← links)
- Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease (Q27003841) (← links)
- Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease (Q27009411) (← links)
- Brain PET in the diagnosis of Alzheimer's disease (Q27011549) (← links)
- Development of positron emission tomography β-amyloid plaque imaging agents (Q27012742) (← links)
- Profile of gantenerumab and its potential in the treatment of Alzheimer's disease (Q27027675) (← links)
- Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab (Q27684692) (← links)
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease (Q28005463) (← links)
- Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways (Q28081678) (← links)
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease (Q30557788) (← links)
- Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. (Q30561855) (← links)
- Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease (Q30651551) (← links)
- Imaging endpoints for clinical trials in Alzheimer's disease (Q30885979) (← links)
- First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease (Q31050126) (← links)
- Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients (Q31171988) (← links)
- Mild to moderate Alzheimer dementia with insufficient neuropathological changes (Q33592693) (← links)
- Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer (Q33604583) (← links)
- Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases (Q33731321) (← links)
- Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study (Q33746272) (← links)
- Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis (Q33777535) (← links)
- Positron emission tomography radioligands for in vivo imaging of Aβ plaques (Q33874024) (← links)
- Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. (Q34091134) (← links)
- Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. (Q34240270) (← links)
- Should we disclose amyloid imaging results to cognitively normal individuals? (Q34286140) (← links)
- Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications (Q34345602) (← links)
- Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 (Q34408888) (← links)
- The preclinical Alzheimer cognitive composite: measuring amyloid-related decline (Q34422469) (← links)
- Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease (Q34528767) (← links)
- Amyloid-ß-directed immunotherapy for Alzheimer's disease (Q34548700) (← links)
- Novel immunological approaches for the treatment of Alzheimer's disease (Q34562675) (← links)
- Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. (Q34584517) (← links)
- An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion (Q34597563) (← links)
- Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology? (Q34629872) (← links)
- Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. (Q34735142) (← links)
- First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study (Q35195612) (← links)
- Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials (Q35695716) (← links)
- Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration (Q35826425) (← links)
- Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. (Q35840623) (← links)
- Could immunomodulation be used to prevent prion diseases? (Q35875915) (← links)
- Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice (Q35898132) (← links)
- Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors. (Q35972878) (← links)
- Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (Q36005648) (← links)